Genetic Testing for Breast Cancer Response Prediction
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well genetic testing works in predicting tumor response in patients with stage I-III HER2 negative invasive breast cancer. Genetic testing is a procedure that tests tumor samples to learn if certain genes are activated (turned on) in the tumor and if the activation of these genes may predict if the tumor will be sensitive or resistant to routine breast cancer treatments, such as chemotherapy or hormonal therapy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is genetic testing for breast cancer generally safe for humans?
How does genetic testing for breast cancer response prediction differ from other treatments?
This treatment is unique because it uses genetic testing to predict how a person with breast cancer might respond to different treatments, allowing for more personalized and potentially effective treatment plans. Unlike standard treatments that are generally applied to all patients, this approach tailors the treatment based on individual genetic information.678910
What data supports the effectiveness of genetic testing as a treatment for breast cancer response prediction?
Genetic testing helps personalize breast cancer treatment by identifying specific genetic mutations, which can guide doctors in choosing the most effective therapies and assessing cancer recurrence risk. It has been shown to improve treatment decisions and outcomes by tailoring strategies to individual genetic profiles, as seen with the use of BRCA1/2 testing and other high-risk genes.511121314
Who Is on the Research Team?
Senthilkumar Damodaran
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with stage I-III HER2 negative invasive breast cancer, who have a tumor at least 1 cm in diameter and can undergo biopsy or surgery. It's not for those who had prior breast cancer treatments, other cancers within the last 5 years (except certain skin cancers), or tumors obscured by hematoma/biopsy changes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic
Patients undergo biopsy or surgery to obtain tumor sample for genetic testing
Treatment Assignment
Patients are assigned to 4 treatment cohorts as determined by genetic test results
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Genetic Testing
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator